Applied DNA Sciences, Inc.
APDN
$0.1314
$0.00181.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -58.46% | -74.33% | -78.96% | -68.52% | -53.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -58.46% | -74.33% | -78.96% | -68.52% | -53.31% |
| Cost of Revenue | -59.58% | -69.18% | -75.21% | -69.35% | -56.67% |
| Gross Profit | -56.60% | -81.62% | -85.51% | -66.76% | -46.43% |
| SG&A Expenses | -16.76% | -10.22% | -8.50% | -1.93% | 1.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.79% | -28.22% | -32.59% | -30.13% | -24.30% |
| Operating Income | 2.39% | -28.05% | -35.25% | -30.86% | -29.01% |
| Income Before Tax | -18.03% | 29.28% | -4.50% | -143.07% | 1.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.03% | 29.28% | -4.50% | -143.07% | 1.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -0.30% | 26.22% | 89.96% | 115.75% | 2,469.23% |
| Net Income | -18.28% | 29.70% | -3.85% | -143.29% | 2.44% |
| EBIT | 2.39% | -28.05% | -35.25% | -30.86% | -29.01% |
| EBITDA | -4.45% | -38.97% | -44.46% | -36.84% | -33.00% |
| EPS Basic | 47.62% | 54.49% | -7.69% | -96.56% | 23.41% |
| Normalized Basic EPS | 52.87% | 56.48% | -4.87% | -93.11% | 23.42% |
| EPS Diluted | 47.62% | 54.62% | -7.25% | -95.55% | 23.65% |
| Normalized Diluted EPS | 52.87% | 56.48% | -4.87% | -93.11% | 23.42% |
| Average Basic Shares Outstanding | 1,660.58% | 507.02% | 149.71% | 24.86% | 28.50% |
| Average Diluted Shares Outstanding | 1,660.58% | 507.02% | 149.71% | 24.86% | 28.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
